Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Sanofi ( (SNY) ) has issued an update.
On March 18, 2026, Sanofi announced that the U.S. Food and Drug Administration granted Breakthrough Therapy designation to venglustat, its investigational oral glucosylceramide synthase inhibitor, for treating neurological manifestations of type 3 Gaucher disease. The designation, based on positive phase 3 LEAP2MONO data showing statistically significant neurological benefit versus standard enzyme replacement therapy and a generally well-tolerated safety profile, strengthens Sanofi’s position in rare diseases and sets the stage for global regulatory filings in 2026, potentially bringing the first targeted neurologic treatment option to GD3 patients who currently lack approved therapies for these symptoms.
The LEAP2MONO phase 3 trial compared once-daily oral venglustat with biweekly intravenous enzyme replacement in GD3 patients already stabilized for systemic disease, meeting primary endpoints on measures of ataxia and cognition over 52 weeks. With prior fast-track and orphan designations in major markets, the new Breakthrough status is expected to expedite development and review in the U.S., underscoring the drug’s potential clinical and commercial importance for Sanofi and offering hope of improved outcomes for a small, underserved patient population.
The most recent analyst rating on (SNY) stock is a Hold with a $57.00 price target. To see the full list of analyst forecasts on Sanofi stock, see the SNY Stock Forecast page.
Spark’s Take on SNY Stock
According to Spark, TipRanks’ AI Analyst, SNY is a Outperform.
The score is driven primarily by solid financial resilience and a constructive earnings outlook (growth, margin expansion, and buybacks). Valuation is supportive with a reasonable P/E and strong dividend, while weaker technical trend signals (below major moving averages and negative MACD) temper the overall rating.
To see Spark’s full report on SNY stock, click here.
More about Sanofi
Sanofi is an R&D-driven, AI-powered biopharmaceutical company that develops medicines and vaccines for millions of people worldwide. Leveraging its expertise in the immune system and a broad innovative pipeline, the Paris-based group focuses on addressing urgent healthcare challenges, and is listed on Euronext Paris and Nasdaq under the tickers SAN and SNY.
Average Trading Volume: 4,184,444
Technical Sentiment Signal: Sell
Current Market Cap: $107.2B
See more data about SNY stock on TipRanks’ Stock Analysis page.